Get the Stockscreener App
1.32
0.75%
-0.01
Inmed Pharmaceuticals Inc stock is traded at $1.32, with a volume of 4,339.
It is down -0.75% in the last 24 hours and up +3.12% over the past month.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
See More
Previous Close:
$1.33
Open:
$1.32
24h Volume:
4,339
Relative Volume:
0.17
Market Cap:
$7.25M
Revenue:
$3.25M
Net Income/Loss:
$-8.34M
P/E Ratio:
-0.5125
EPS:
-2.5755
Net Cash Flow:
$-7.71M
1W Performance:
-2.94%
1M Performance:
+3.12%
6M Performance:
+88.57%
1Y Performance:
-36.54%
1-Day Range:
$1.32
$1.34
1-Week Range:
$1.31
$1.40
52-Week Range:
$0.575
$2.33
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
1.32 | 7.25M | 3.25M | -8.34M | -7.71M | -2.5755 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Inmed Pharmaceuticals Inc Stock (INM) Latest News
At $1.32–$1.33 a share, ADAR1 funds buy 9,569 shares of InMed Pharmaceuticals (INM). - Stock Titan
Form 4 InMed Pharmaceuticals Inc. For: 12 October By Investing.com - Investing.com South Africa
Form 4 InMed Pharmaceuticals Inc. For: 8 October By Investing.com - Investing.com South Africa
Form 4 InMed Pharmaceuticals Inc. For: 8 October By Investing.com - Investing.com UK
Across October 6–8, ADAR1 funds buy 10,903 shares of InMed Pharmaceuticals (INM). - Stock Titan
Funds hold 943,668 InMed Pharmaceuticals (INM) shares, with voting power shared by two reporting persons. - Stock Titan
Across three transactions, ADAR1 funds buy 42,920 InMed Pharmaceuticals (INM) shares. - Stock Titan
Form 8K INMED PHARMACEUTICALS INC. For: 18 September By Investing.com - Investing.com Nigeria
Nasdaq gives InMed 45 days to submit a compliance plan - Stock Titan
10% owner adds to InMed Pharmaceuticals (INM) stake with open-market buys - Stock Titan
InMed Reports FY2026 Net Loss Of $12.9 Million As Mentari Merger Advances With $490 Million Financing - Pulse 2.0
InMed winds down only revenue-generating business BayMedica - Minichart
[S-4/A] InMed Pharmaceuticals Inc. Amended Business Combination Registration | INM SEC FilingForm S-4/A - Stock Titan
$490M backs proposed migraine merger at InMed Pharmaceuticals (INM)—what legacy holders keep - Stock Titan
InMed Pharmaceuticals Inc. FY 2026: Revenue $3.18M, EPS ($3.12) — 10-K Summary - TradingView
About $490 million in financing is expected before a proposed merger. InMed still needs shareholder approval. - Stock Titan
InMed Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
InMed (INM) Earnings Update: The Company Publishes Its Latest Results in the Latest Session; Price Reaction: Shares Close 7.59% Lower for the Current SessionSegment Revenue Breakdown - vinanet.vn
InMed (INM) Price: Finishes 7.59% Down at $1.46 in the Latest Session; Technical Setup: Price Remains Between $1.39 Support and $1.53 Resistance under the Current SnapshotIntraday Profile - vinanet.vn
InMed (INM) Price: Finishes 7.59% Down at $1.46 in the Latest Session; Technical Setup: Price Remains Between $1.39 Support and $1.53 Resistance under the Current SnapshotShort Setup Alerts - siam.in
InMed (INM) Price: Finishes 7.59% Down at $1.46 in the Latest Session; Technical Setup: Price Remains Between $1.39 Support and $1.53 Resistance under the Current SnapshotVol Target Rebalance - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateEarnings Growth Forecast - vinanet.vn
InMed (INM) Session: Adds 0.63% to Close at $1.60 in Latest Trading; Current Setup: Traders Can Monitor the $1.52-$1.68 RangeVolatility Skew - vinanet.vn
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateAnalyst Earnings Estimate - careplusvn.com
InMed (INM) Session: Adds 0.63% to Close at $1.60 in Latest Trading; Current Setup: Traders Can Monitor the $1.52-$1.68 RangeBollinger Walk - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateNegative Surprise Momentum - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateAnalyst Consensus Shift - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateRevenue Per Share - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateEarnings Surprise Stocks - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateUpward Estimate Revision - dars.gov.et
InMed Pharmaceuticals (INM) Holds Above Support After 2.8% GainCash Secured Put - vinanet.vn
InMed Pharmaceuticals (INM) Holds Above Support After 2.8% GainKey Reversal Day - dars.gov.et
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share; Stock Rises 2.8%One-Time Gain Impact - vinanet.vn
InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares - Stock Titan
Inmed Pharmaceuticals Stock Price Forecast. Should You Buy INM? - StockInvest.us
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share Reflects Ongoing Biopharmaceutical InvestmentRevenue Breakdown Analysis - vinanet.vn
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share ReportedFinancial Data - Vinanet
InMed Pharmaceuticals (INM) Rises 3.55% to $1.46 as Buyers Defend Key SupportMA Crossover - dars.gov.et
InMed Pharmaceuticals (INM) Rises 3.55% to $1.46 as Buyers Defend Key SupportBlue Chip Entry Points - vinanet.vn
InMed Pharmaceuticals Inc (INM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InMed Pharmaceuticals (INM) Slips 6% to $1.40 as Support Level Comes into FocusDefined Outcome ETF - vinanet.vn
InMed Pharmaceuticals (INM) Rises 2.40% as Shares Approach Key $1.58 ResistanceSector Leader Stocks - vinanet.vn
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share Reflects Ongoing Clinical InvestmentNet Profit Margin - vinanet.vn
INM Q3 2025 Earnings: Narrowing Losses and Cautious Pipeline ProgressRevenue Growth Report - vinanet.vn
InMed Pharmaceuticals Inc (INM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InMed Pharmaceuticals Inc (INM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InMed Pharmaceuticals Inc (INM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InMed Pharmaceuticals Inc (INM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InMed Pharmaceuticals Inc (INM) Institutional Confidence - TradingKey
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmed Pharmaceuticals Inc Stock (INM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 15 '26 |
Buy |
1.32 |
984 |
1,301 |
955,493 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 13 '26 |
Buy |
1.33 |
564 |
750 |
946,488 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 08 '26 |
Buy |
1.33 |
2,256 |
2,997 |
945,924 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 07 '26 |
Buy |
1.33 |
3,046 |
4,051 |
943,668 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 06 '26 |
Buy |
1.33 |
5,601 |
7,436 |
940,622 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 05 '26 |
Buy |
1.33 |
18,182 |
24,182 |
935,021 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 02 '26 |
Buy |
1.33 |
8,307 |
11,048 |
916,839 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 01 '26 |
Buy |
1.33 |
16,431 |
21,850 |
908,532 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 16 '26 |
Buy |
1.29 |
8,340 |
10,750 |
892,101 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 15 '26 |
Buy |
1.30 |
54,256 |
70,446 |
883,761 |
7.97%
3.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):